0000899243-20-020730.txt : 20200730
0000899243-20-020730.hdr.sgml : 20200730
20200730090049
ACCESSION NUMBER: 0000899243-20-020730
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200728
FILED AS OF DATE: 20200730
DATE AS OF CHANGE: 20200730
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davis Aaron I.
CENTRAL INDEX KEY: 0001465914
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 201059436
MAIL ADDRESS:
STREET 1: 11682 EL CAMINO REAL, SUITE 320
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iTeos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001808865
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-204-4583
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-28
0
0001808865
iTeos Therapeutics, Inc.
ITOS
0001465914
Davis Aaron I.
C/O ITEOS THERAPEUTICS, INC.
139 MAIN STREET
CAMBRIDGE
MA
02142
1
0
1
0
Common Stock
2020-07-28
4
C
0
2943568
A
2943568
I
See Footnote
Common Stock
2020-07-28
4
C
0
48691
A
48691
I
See Footnote
Common Stock
2020-07-28
4
P
0
1401448
19.00
A
4345016
I
See Footnotes
Common Stock
2020-07-28
4
P
0
23552
19.00
A
72243
I
See Footnotes
Series B-2 Preferred Stock
2020-07-28
4
C
0
9593086
D
Common Stock
2943568
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
158687
D
Common Stock
48691
0
I
See Footnote
Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.
The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
These securities are owned directly by Boxer Capital, which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
These securities are owned directly by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
On July 28, 2020, Boxer Capital purchased 1,401,448 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering..
On July 28, 2020, MVA Investors purchased 23,552 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
/s/ Michel Detheux, as Attorney-in-Fact
2020-07-30